Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation

Biol Blood Marrow Transplant. 2010 Nov;16(11):1603-7. doi: 10.1016/j.bbmt.2010.05.015. Epub 2010 Jun 1.


Five patients with aggressive acute leukemias who had relapsed after cord blood transplantation were treated with cord blood derived cytokine-induced killer (CIK) cells. These were obtained by ex vivo expansion, using as starting material the washouts of the cord blood units, left over at the end of the transplant. We did not observe any acute or delayed adverse event, and observed 1 partial response in 1 patient concomitantly with the development of acute grade III graft-versus-host disease (GVHD). These observations show the relatively low toxicity of cord blood-derived CIK cells and, more importantly, the feasibility of this immunotherapy program for patients who could not otherwise benefit from donor lymphocyte infusions.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cord Blood Stem Cell Transplantation*
  • Cytokine-Induced Killer Cells / cytology
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / transplantation*
  • Cytotoxicity Tests, Immunologic
  • Female
  • Fetal Blood / cytology
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / epidemiology
  • Humans
  • Immunotherapy, Adoptive / adverse effects*
  • Immunotherapy, Adoptive / methods*
  • K562 Cells
  • Leukemia / immunology
  • Leukemia / mortality
  • Leukemia / therapy*
  • Male
  • Mesenchymal Stem Cell Transplantation
  • Middle Aged
  • Recurrence
  • Survival Analysis
  • Treatment Outcome